Sells prescription medicines for tardive dyskinesia, Huntington’s chorea and congenital adrenal hyperplasia through specialty pharmacies and distributors, and develops treatments for neurological, psychiatric, endocrine and immunological disorders.
10-K for FY2025, filed Feb 11, 2026Our portfolio of products includes U.S. Food and Drug Administration (FDA) approved treatments for tardive dyskinesia (TD), chorea…View ↗
We launched INGREZZA® (valbenazine) in the U.S. as the first FDA-approved drug for the treatment of TD in May 2017 and for the treatment of…View ↗
We sell INGREZZA exclusively in the U.S. through a limited specialty network. Our customers include select specialty pharmacy providers…View ↗
Product sales come from medicines sold through specialty pharmacies and distributors, with sales counted when customers obtain the products; collaboration revenue mainly comes from royalties on AbbVie and Tanabe sales.
10-K for FY2025, filed Feb 11, 2026We sell INGREZZA® (valbenazine) exclusively in the U.S. through a limited specialty network. Our customers include select specialty…View ↗
We recognize revenue when the customer obtains control of promised goods or services in an amount that reflects the consideration which we…View ↗
Collaboration revenues for all periods presented primarily reflected royalties earned on AbbVie net sales of elagolix and Tanabe Pharma…View ↗
10-K for FY2025, filed Feb 11, 2026
FY2025 revenue by product or service ↗$2.9B
10-K for FY2025, filed Feb 11, 2026
$2.9B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product sales
Sold outright
10-K for FY2025, filed Feb 11, 2026 |
99%
FY2022: 97%
|
Net product sales, FY2025
$2.8B Sources
|
Sold outright |
|
Collaboration revenues
Licensed
|
0.9%
FY2022: 3.2%
|
Collaboration revenues, FY2025
$26.6M Sources
|
Licensed |
INGREZZA is sold through select specialty pharmacy providers, wholesale distributors and specialty distributors; CRENESSITY is sold through a single specialty pharmacy provider.
10-K for FY2025, filed Feb 11, 2026We sell INGREZZA exclusively in the U.S. through a limited specialty network. Our customers include select specialty pharmacy providers…View ↗
Yes. It kept 17 cents of every revenue dollar as net income in FY2025 and turned 26 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 2, 2026
$206.5MView ↗
10-Q for Q3 FY2026, filed Nov 2, 2026
Open tableView ↗
8-K, filed Jul 30, 2026
Total revenues for the second quarter 2026 were $959 million, compared with $688 million in the prior-year period representing 39%…View ↗
8-K, filed May 18, 2026
The Company completed the acquisition of Soleno on May 18, 2026, by causing Purchaser to merge with and into Soleno (the “Merger”) pursuant…View ↗
Growing. Revenue grew 2.5x in 4 years, from $1.1B in FY2021 to $2.9B in FY2025, about 26% a year.
Additional treatment uses
Valbenazine has expanded from a tardive dyskinesia treatment in the older report to also treat Huntington’s chorea; the latest report also describes crinecerfont as a launched treatment for congenital adrenal hyperplasia.
10-K for FY2022, filed Feb 9, 2023 10-K for FY2025, filed Feb 11, 2026INGREZZA® (valbenazine). We launched INGREZZA in the United States in May 2017 as the first FDA-approved product for the treatment of…View ↗
We launched INGREZZA® (valbenazine) in the U.S. as the first FDA-approved drug for the treatment of TD in May 2017 and for the treatment of…View ↗
Competes with Teva Pharmaceuticals Industries
10-K for FY2025, filed Feb 11, 2026INGREZZA competes with AUSTEDO (deutetrabenazine), marketed by Teva Pharmaceuticals Industries, for the treatment of TD in adults and…View ↗
Loading...